|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2000-9-14
|
|
pubmed:abstractText |
Advanced glycation is postulated to have a pivotal role in mediating diabetic vascular complications. The emergence of thiazolium compounds such as N-phenacylthiazolium bromide which cleave preformed advanced glycation end products (AGEs) has allowed us to explore the effects of these agents on the vascular AGE accumulation and hypertrophy associated with diabetes.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0012-186X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
43
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
660-4
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:10855541-Animals,
pubmed-meshheading:10855541-Blood Pressure,
pubmed-meshheading:10855541-Blood Vessels,
pubmed-meshheading:10855541-Diabetes Mellitus, Experimental,
pubmed-meshheading:10855541-Glycosylation End Products, Advanced,
pubmed-meshheading:10855541-Hemoglobin A, Glycosylated,
pubmed-meshheading:10855541-Immunohistochemistry,
pubmed-meshheading:10855541-Male,
pubmed-meshheading:10855541-Rats,
pubmed-meshheading:10855541-Rats, Sprague-Dawley,
pubmed-meshheading:10855541-Splanchnic Circulation,
pubmed-meshheading:10855541-Thiazoles
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
The cross-link breaker, N-phenacylthiazolium bromide prevents vascular advanced glycation end-product accumulation.
|
|
pubmed:affiliation |
Department of Medicine, University of Melbourne, Austin and Repatriation Medical Centre, West Heidelberg, Australia.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
